<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53653">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917331</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1207-PR-0091</org_study_id>
    <nct_id>NCT01917331</nct_id>
  </id_info>
  <brief_title>Efficacy of Fixed Combination of Beclomethasone + Formoterol + Glycopyrrolate Versus Foster® in Chronic Obstructive Pulmonary Diseases</brief_title>
  <official_title>A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone+Formoterol+Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Czech Republic: Ministry of Health</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to
      demonstrate the superiority of the triple fixed combination of
      Beclometasone+Formoterol+Glycopyrrolate administered via pMDI over the equivalent dose of
      Foster® in COPD (Chronic Obstructive Pulmonary Disease) patients after 52 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pre-dose and 2-hour post-dose morning FEV1 at week 26 and TDI score at week 26</measure>
    <time_frame>week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in pre-dose morning FEV1 at Week 26.
Change from baseline to the 2-hour post-dose value of FEV1 at Week 26.
TDI focal score at Week 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD exacerbation rate</measure>
    <time_frame>week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Moderate and severe COPD exacerbation rate over 52 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1863</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Beclometasone/Formoterol/Glycopyrrolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beclometasone/Formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Foster® 100/6 mcg 2 inhalations bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone/Formoterol/Glycopyrrolate</intervention_name>
    <arm_group_label>Beclometasone/Formoterol/Glycopyrrolate</arm_group_label>
    <other_name>BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone/Formoterol</intervention_name>
    <arm_group_label>Beclometasone/Formoterol</arm_group_label>
    <other_name>Foster® or CHF 1535 pMDI 100/6 mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged ≥ 40 years with a diagnosis of COPD

          -  Current smokers or ex-smokers

          -  A post-bronchodilator FEV1 &lt; 50% of the predicted normal value and a post-
             bronchodilator FEV1/FVC &lt; 0.7

          -  At least one exacerbation in the 12 months preceding the screening visit

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of asthma or history of allergic rhinitis or atopy

          -  Patients treated with non-cardioselective β-blockers in the month preceding the
             screening visit

          -  Patients treated for exacerbations in the 4 weeks prior to screening visit

          -  Patients treated with long-acting antihistamines  unless taken at stable regimen at
             least 2 months prior to screening and to be maintained constant during the study or
             if taken as PRN

          -  Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic
             hypoxemia

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave SINGH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of South Manchester, MANCHESTER M23 9 QZ, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marisa MINETTI</last_name>
    <phone>+39 0521 279 715</phone>
    <email>m.minetti@chiesi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine FRANCISCO</last_name>
    <phone>+33 1 47 68 48 59</phone>
    <email>c.francisco@chiesi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr Beatrix BALINT</name>
      <address>
        <city>Szeged</city>
        <zip>6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrix BALINT, Dr</last_name>
      <phone>0036-62-571-512</phone>
      <email>balint@deszkikorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Beatrix Balint, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spirometry</keyword>
  <keyword>severe COPD</keyword>
  <keyword>lung disease</keyword>
  <keyword>fixed combination</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Formoterol</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
